Compare Davita Inc (DVA) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs L3Harris Technologies Inc — how do they compare? Davita Inc trades at $179.54 (market cap $11.38B), while L3Harris Technologies Inc trades at $284.76 (market cap $53.26B). The key difference: L3Harris Technologies Inc is far larger — about 4.7× Davita Inc's market cap, and L3Harris Technologies Inc pays a 1.75% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | LHX | |
|---|---|---|
Market Cap | $11.38B | $53.26B |
Sector | Health | Industrials |
52-Week High | $240.96 | $378.48 |
52-Week Low | $103.87 | $270.21 |
Enterprise Value | $24.10B | $63.71B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
LHX trades at $289.72, up 1.06% on the day, with a bearish technical signal but strong fundamental momentum. Recent earnings beats, including Q2 2026 EPS of $3.13 versus $2.80 expected, and a record $42 billion backlog support growth. The company completed a strategic divestiture and secured key defense contracts, enhancing its positioning in missile defense and space systems.
Outlook is positive with analyst consensus price target of $319.33 implying ~10% upside, though technical indicators signal near-term caution. Risks include execution on production ramp-ups and defense budget volatility, but robust cash flow and dividend payments provide shareholder stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
